Strides Pharma Science shines as its arm acquires identified ANDAs from Nostrum Laboratories, Inc, USA
Strides Pharma Science is currently trading at Rs. 670.25, up by 17.70 points or 2.71% from its previous closing of Rs. 652.55 on the BSE.
The scrip opened at Rs. 665.75 and has touched a high and low of Rs. 672.95 and Rs. 651.25 respectively. So far 9340 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 804.12 on 17-Oct-2024 and a 52 week low of Rs. 329.76 on 4-Jun-2025.
Last one week high and low of the scrip stood at Rs. 707.20 and Rs. 640.80 respectively. The current market cap of the company is Rs. 6177.21 crore.
The promoters holding in the company stood at 28.30%, while Institutions and Non-Institutions held 42.05% and 29.65% respectively.
Strides Pharma Science’s step-down wholly owned subsidiary -- Strides Pharma Inc., has acquired four approved ANDAs for the US Market from Nostrum Laboratories, Inc., USA.
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with Urinary Tract Infections (UTIs), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy.
The cumulative market size for the acquired portfolio is around $57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is $2.075 million (around Rs 17.60 crore). Two (out of the Four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products.
StridesPharmaScience (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
